Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

The following table reflects, as of September 30, 2025, the carrying values and remaining useful lives of acquired intangible assets:


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Value		Weighted-Average Amortization Period (in years)
Tradenames and trademarks	$	54,500	$	(10,802)	$	43,698	12.8
Developed technology	62,900		(21,190)		41,710		6.0
Customer relationships	104,100		(16,923)		87,177		16.4
Total intangible assets	$	221,500	$	(48,915)	$	172,585	13.0

Amortization expense for tradenames and trademarks and developed technology of $2.8 million and $2.3 million was recorded in general and administrative for the three months ended September 30, 2025 and 2024, respectively, and $7.7 million and $6.8 million for the nine months ended September 30, 2025 and 2024, respectively, within the condensed consolidated statements of operations and comprehensive loss. Amortization expense for customer relationships of $1.3 million and $1.2 million was recorded in selling and marketing for the three months ended September 30, 2025 and 2024, respectively, and $3.9 million and $3.7 million for the nine months ended September 30, 2025 and 2024, respectively, within the condensed consolidated statements of operations and comprehensive loss.

As discussed in Note 3, “Business Combinations” included within this Quarterly Report, the acquisition of Fabric Genomics resulted in the initial recognition of $12.9 million of goodwill as of the Merger Date. The purchase price allocation for acquired businesses may be modified for up to one year from the date of acquisition if additional facts or circumstances lead to changes in the Company’s preliminary purchase accounting estimates.

The following table reflects changes to the carrying amount of goodwill between the Merger Date and September 30, 2025:


Balance at May 5, 2025	$	12,926

Measurement period adjustments	(128)

Balance at September 30, 2025	$	12,798

GeneDx Holdings Corp. 10-Q